Subcutaneous transplantation of islets into streptozocin-induced diabetic rats.
Pancreatic islet transplantation into type 1 diabetic patients is currently being performed by intraportal infusion. This method, albeit reproducible, has some disadvantages including potential development of portal hypertension, hemorrhage, and an inability to retrieve or detect the transplanted tissue. Other transplant sites have been examined in animal models including the omentum, peritoneal cavity, and the spleen. A transplant site that has not been successful in supporting functional islet tissue transplantation in humans is the subcutaneous space due primarily to the lack of a well-defined vascular bed. This site has many favorable characteristics such as ease of access for transplantation and potential for removal of the transplanted tissue with a minimally invasive surgical procedure. This report addresses the evaluation of a subcutaneously placed device for the support of rat syngeneic islet transplantation in a streptozocin-induced diabetic model. The data generated support the use of this device for islet engraftment. In addition, beta cell function in this device compared favorably with the function of islets transplanted to the renal subcapsular space as well as islets within the native pancreas.
Halberstadt
Craig R
CR
Department of General Surgery, Carolinas Medical Center, Charlotte, NC 28232, USA. chalberstadt@carolinas.org
Williams
Deana
D
Emerich
Dwaine
D
Goddard
Moses
M
Vasconcellos
Alfred V
AV
Curry
William
W
Bhatia
Aashim
A
Gores
Paul F
PF
D000818:Animals; D062109:Dermatologic Surgical Procedures; D003921:Diabetes Mellitus, Experimental / Q000628:therapy*; D005260:Female; D016381:Islets of Langerhans Transplantation; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley